Photocure ASA, the Bladder Cancer Company, has entered into a strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope.

膀胱癌公司Photocure ASA已与Richard Wolf GmbH签订战略协议，开发并商业化下一代4K LED高清（HD）可重复使用的柔性蓝光膀胱镜。

The partnership between Photocure and Richard Wolf is focused on developing technologically advanced flexible blue light cystoscopy (BLC) equipment for the global market so that physicians who treat patients with bladder cancer can offer the benefits of BLC with Hexvix/ Cysview in an outpatient, or surveillance setting..

Photocure和Richard Wolf的合作伙伴关系专注于为全球市场开发技术先进的柔性蓝光膀胱镜（BLC）设备，以便治疗膀胱癌患者的医生可以在门诊或监测环境中使用Hexvix/Cysview提供BLC的益处。。

The strategic partnership between Photocure and Richard Wolf builds off a longstanding relationship between the two companies associated with co-promotion, disease awareness, education, market development, and clinical research.

Photocure和Richard Wolf之间的战略合作关系建立了两家公司之间的长期关系，这些关系涉及共同推广，疾病意识，教育，市场开发和临床研究。

“Entering into this partnership with Richard Wolf is a milestone for Photocure, and more importantly is the first step toward making high-definition BLC equipment in the surveillance setting consistently available for patients globally,” said Dan Schneider, President and CEO of Photocure. “Before the phase-down of standard-definition flexible blue light equipment in the U.S., adoption of these systems was on a strong growth path with physicians recognizing the significant benefits of precision monitoring of bladder tumors with BLC and Cysview.

Photocure总裁兼首席执行官丹·施奈德（DanSchneider）表示：“与理查德·沃尔夫（RichardWolf）建立这种合作关系是Photocure的一个里程碑，更重要的是，这是朝着使全球监测环境中的高清BLC设备始终可供患者使用迈出的第一步。”。“在美国逐步停止使用标准清晰度柔性蓝光设备之前，这些系统的采用呈强劲增长趋势，医生认识到使用BLC和Cysview精确监测膀胱肿瘤的重大益处。

We look forward to working with Richard Wolf on the development and anticipated commercialization of a 4K high-definition blue light cystoscope and bringing a cutting-edge and cost-effective solution to physicians and patients in our commercial territories as soon as possible.”.

我们期待着与Richard Wolf合作，开发4K高清蓝光膀胱镜并将其商业化，并尽快为我们商业领域的医生和患者带来尖端且具有成本效益的解决方案。”。

Under the Agreement, Richard Wolf will develop the new flexible BLC system with input and guidance from Photocure, using Photocure’s knowledge of the surveillance procedure and experience with urology customers. It will also be based on Richard Wolf’s System blue technology.

根据协议，Richard Wolf将利用Photocure的监测程序知识和泌尿科客户的经验，利用Photocure的输入和指导，开发新的灵活BLC系统。它还将基于Richard Wolf的System blue技术。

The new flexible blue light system and underlying intellectual property will be owned by Richard Wolf, who will also serve as the sponsor of market authorizations around the world.

新的灵活的蓝光系统和基础知识产权将由Richard Wolf拥有，他还将作为全球市场授权的赞助商。

Photocure and Richard Wolf will share expenses for the development and regulatory activities necessary for approvals of the HD flexible blue light system in markets where it will be commercialized. Photocure and Richard Wolf will co-promote the new blue light flexible system in the U.S., Europe, and other countries globally..

Photocure和Richard Wolf将分担HD柔性蓝光系统在商业化市场获得批准所需的开发和监管活动的费用。Photocure和Richard Wolf将在美国、欧洲和全球其他国家共同推广新的蓝光柔性系统。。

Photocure will utilize data from existing patient registries to leverage real-world evidence to further support the benefits of flexible blue light cystoscopy for patients with non-muscle invasive bladder cancer. Per the agreement, Photocure and Richard Wolf will establish two governance committees to oversee the progress of the collaboration including a Joint Development Committee to ensure R&D milestones are successfully achieved and a Joint Commercialization Committee to execute pre- and post-approval go-to-market strategies globally..

Photocure将利用现有患者登记处的数据，利用现实世界的证据，进一步支持柔性蓝光膀胱镜检查对非肌肉浸润性膀胱癌患者的益处。根据该协议，Photocure和Richard Wolf将成立两个治理委员会来监督合作的进展，包括一个联合发展委员会，以确保研发里程碑的成功实现，以及一个联合商业化委员会，以在全球范围内执行批准前和批准后的上市战略。。

“As a full-service provider in endoscopy and a leading manufacturer of blue light cystoscopy equipment, we are very pleased to enter into this Agreement with Photocure, to develop and commercialize a first-in-class/best-in-class high-definition flexible blue light system,” said Florian Happe, Vice President R&D at Richard Wolf.

Richard Wolf研发副总裁Florian Happe说：“作为内窥镜检查的全方位服务提供商和蓝光膀胱镜设备的领先制造商，我们很高兴与Photocure签订这项协议，开发并商业化一流/一流的高清柔性蓝光系统。”。

“The workmanship that goes into every Richard Wolf device provides the foundation for exceptional precision and longevity in the clinical setting, enabling our institutional and physician customers to deliver excellence in care to their patients. Surveillance of patients with bladder cancer is of critical importance in disease management, and we believe that a high-definition blue light cystoscope designed for out-patient use has potential to set a new standard in this care setting.”.

“每台Richard Wolf设备的工艺都为临床环境中异常精确和长寿奠定了基础，使我们的机构和医生客户能够为患者提供卓越的护理。对膀胱癌患者的监测在疾病管理中至关重要，我们相信专为门诊使用而设计的高清蓝光膀胱镜有可能在这种护理环境中树立新的标准。”。

Photocure will leverage its existing sales organization to promote the new reusable flex system in North America and Europe and will rely on Richard Wolf distributors or commercial partners to co-promote the device in other markets.

Photocure将利用其现有的销售组织在北美和欧洲推广新的可重复使用的flex系统，并将依靠Richard Wolf分销商或商业合作伙伴在其他市场共同推广该设备。

Photocure’s previously approved blue light has now been available since 2023. With this partnership, the company is dedicated to ensuring that BLC with Hexvix/Cysview is available to physicians worldwide in both the surgical and surveillance settings so that patients with bladder cancer can have access to the best care..

Photocure先前批准的蓝光灯现已于2023年上市。通过这种合作关系，该公司致力于确保BLC与Hexvix/Cysview在手术和监测环境中均可供全球医生使用，以便膀胱癌患者获得最佳护理。。